Myqorzo Launch Underway Amid Competitive Headwinds

What happened

Cytokinetics has begun commercializing Myqorzo (aficamten) for obstructive HCM following FDA approval, with early U.S. uptake and European expansion supporting initial momentum. However, the drug enters a market dominated by Bristol Myers Squibb's Camzyos, which treated over 12,500 U.S. patients by mid-2025 and has a simplified REMS that narrows Myqorzo's differentiation. The company still lacks a commercial track record and carries a leveraged balance sheet with negative equity, burning ~$100 million per quarter pre-launch. While the Zacks article frames Myqorzo's approval as a positive driver, the DeepValue master report highlights that valuation at ~$63 per share discounts aggressive share capture assumptions that may prove optimistic. Risk-reward skews to downside given the crowded bullish positioning and reliance on flawless execution for the next 12–18 months.

Implication

Investors should wait for concrete evidence of Myqorzo's market share gains and payer acceptance before building positions. The base case implies fair value near current levels, but bear case downside to $40 is material if launch disappoints or ACACIA fails. Monitor early prescription trends and REMS enrollment as key leading indicators.

Thesis delta

The post-approval narrative is shifting from regulatory binary to commercial execution, but the structural challenges—entrenched incumbent, leveraged balance sheet, and high expectations—remain unchanged. The new article does not alter the bearish skew from the DeepValue report; if anything, it reinforces the need to see actual sales traction before becoming constructive.